Previous 10 |
- Completes eptinezumab’s Biologics License Application (BLA) submission - - Remains on track for eptinezumab’s commercial launch in Q1-2020 - - Strengthens leadership team with the appointments of Carlos Campoy as Chief Financial Officer and Dr. Paul Streck as C...
BOTHELL, Wash., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced it has submitted a Biologics License Application (BLA) to the U.S. F...
BOTHELL, Wash., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder’s president and chief executive officer...
BOTHELL, Wash., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its fourth quarter and year-end 2018 financial a...
Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its ...
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Varonis Systems, Inc. (NASDAQ:VRNS), Dolby Laboratories (NYSE:DLB), Alder...
BOTHELL, Wash., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors ...
News, Short Squeeze, Breakout and More Instantly...
Alder BioPharmaceuticals Inc. Company Name:
ALDR Stock Symbol:
NASDAQ Market:
Alder BioPharmaceuticals Inc. Website:
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD191...
Shares of Alder Biopharmaceuticals (NASDAQ: ALDR) jumped 111% in September, according to data provided by S&P Global Market Intelligence , after the biotech said it will be acquired by Lundbeck. Lundbeck, a fairly large drugmaker in Denmark, is after Alder Pharmaceuticals' migraine m...